department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Vumerity · pharmadog

pharmadog
drugs
Vumerity

drug

patient view →

diroximel fumarate DR

Marketedupdated 2mo ago

by $BIIB BIOGEN INC.

Approved

community read0 votes

all catalysts(1)

approval · 1

DIROXIMEL FUMARATE — FDA approval

diroximel fumarate DR

News(0)

no news has mentioned this drug yet

brand

Vumerity

generic

diroximel fumarate

indication

Relapsing Remitting Multiple Sclerosis (RRMS)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 20, 2033

~7.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Oct 29, 2033compositionUS 8669281
Sep 20, 2033compositionUS 10080733
Sep 20, 2033method-of-use (U-1384)US 9090558

🐶 often sniffed alongside

top 3

tagApproval2 co-mentions · 1 sources
drugDIROXIMEL FUMARATE1 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources

Trials studying diroximel fumarate DR

—A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babiesactive not recruitingn=1,178
—A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosisrecruitingn=800
phase3A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)not yet recruitingn=185
phase3A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)completedn=136
—A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)active not recruitingn=10,500
—Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)recruitingn=908
—Study of Diroximel Fumarate in the Real-World Settingterminatedn=75